mercredi 11 avril 2018

Onco Actu du 11 avril 2018

1. Biologie

More than half your body is not human [BBC News]

A tale of the two-faced macrophage and cancer [Stanford Medicine]

When normal is the favoured type [The Darwin Cancer Blog]

1.4 Biologie - Technos

New way to understand tumor diversity combines CRISPR with genetic barcodes [Stanford Medicine]

4.2 Dép., diag. & prono. - Génome

23andMe CEO Compares DNA Tests to at-Home Pregnancy Tests, but It's Not That Simple [Gizmodo]

Helix Takes Clinical Genetic Testing Straight to Consumers [Wired]

5.1 Traitements - Pré-clinique

New class of drugs could help tackle treatment-resistant cancers [Imperial College]

Virus’s ‘taste’ for unusual sugar could lead to new cancer treatments [Imperial College]

5.10 Traitements - Essais

New Drug Combo Improves Survival of Women with Rare Uterine Cancer [Johns Hopkins]

Missing Data [Annals of Internal Medicine]

5.12 Immunothérapies

Cutting-edge cancer drug hobbled by diagnostic test confusion [Nature]

5.2 Pharma

Novartis offloads failed cancer drug to Oncology Venture [FierceBiotech]

Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery [Pfizer]

Pfizer’s PhIII kidney cancer study for Inlyta flops as investigators flag a dead end on outcomes [EndPoints]

Biotech resurrects a long faded Novartis cancer drug star, using a biomarker strategy to push ahead [EndPoints]

5.2.1 Pharma - Partenariats

Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics [Loxo Oncology]

Loxo, Illumina to partner for diagnostic tool targeting cancer [Reuters]

5.2.3 Pharma - économie

More than 2 years after the ugly roci debacle, Clovis says that the SEC is prepping civil charges [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA,...)

FDA Approves Rucaparib for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [ESMO]

5.4 Traitements - Economie

NICE no for Roche’s Alecensa [PharmaTimes]

5.9.8 AACR - Pharma

Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018 [Amgen]

6. Lutte contre les cancers

Collaboration is the key to cancer research [Nature]

6.4 Médico-éco

Physician payments linked to scripts for cancer drugs from Novartis, Pfizer and more: study [FiercePharma]

6.6 Publications

In Latest Sign of Its Resurgence, Clarivate Acquires Kopernio [The Scholarly Kitchen]

Web of Science owner buys tool that offers one-click access to journal articles [Nature]

French say ‘no deal’ to Springer as journal fight spreads [Times Higher Education]

6.8 Communication

A cancer doctor speaks out: How premature hype about experimental drugs fails patients [HealthNewsReview]